News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
The drug will be manufactured at the group’s topical facility at Ahmedabad
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Subscribe To Our Newsletter & Stay Updated
